Sign In   Register
SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("SKYE" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph...
SAN DIEGO, CA, June 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("SKYE" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has expanded its Clinical Advi...
THCVHS shows no signs of chromosomal or gene mutations in preclinical studies SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant ...

's () Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortest time possible. He adds that they've identified multiple revenue generating partnering opportunities for its NanoCelle® drug delivery platform which he says can improve the efficacy of multiple medicines and therapeutics.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

The 1,679,000 warrants were issued in the final week of May and were each exercised into one common company share at C$0.75

The warrants had been set to expire in late February or early March of 2022

Canntab Therapeutics Limited () () (FRA:TBF1), the biopharma focused on hard pill cannabis formulations, said it had received C$1,259,250 gross from the early exercise of warrants. 

The 1,679,000 warrants were issued in the final week of May and were each exercised into one common company share at C$0.75. 

READ: Canntab Therapeutics receives export license from Health Canada

The warrants had been set to expire in late February or early March of 2022.

"We are pleased to receive this vote of confidence from our longstanding loyal shareholders, who have voluntarily exercised their warrants long before expiry to further solidify the company's treasury as we continue to press forward on our sales, production and delivery of product. We would like to thank those shareholders that continue to believe and support Canntab," said Canntab's CEO Larry Latowsky in a statement.

EXMceuticals said that the deal will create a new company in the “fast-growing” business segment of hemp and cannabinoid-based product distribution

Following the deal’s close, the companies will operate under the Global Cannabinoids name

EXMceuticals Inc (CSE:EXM) and US cannabis distributor Global Cannabinoids have signed a definitive agreement related to their all-share merger deal.

In a statement, the Canadian cannabis firm said that the deal will create a new company in the “fast-growing” business segment of hemp and cannabinoid-based product distribution.

In parallel with the merger, the two companies are raising C$6 million via a financing to power the transaction.

READ: EXMceuticals unveils proposed merger with Global Cannabinoid; launches private placement for up to C$6.0M

It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun

The first trial is a randomized, double-blinded, controlled human clinical study expected to involve 24 volunteers with symptoms of either pre-hypertension or mild hypertension

Lexaria Bioscience Corp () () revealed that its first human clinical trial assessing its DehydraTECH CBD technology to treat high blood pressure - HYPER-H21-1 - is now officially underway. 

It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun, the company told investors. 

READ: Lexaria Bioscience says DehyrdaTECH CBD client's product featured in New Hope Network best of 2020 list 

"Dosing is expected to be completed, on schedule, within several weeks, and we may be in a position to report preliminary data in July or thereabouts," said Chris Bunka, Lexaria CEO.

"Despite challenges in launching a human clinical study during a global pandemic, Lexaria’s Europe-based research partners have done an excellent job of balancing the need for scientific validation for a potential new hypertension treatment, with the required safety protocols currently in place."

Lexaria provided Amari with its DehydraTECH technology, which delivers CBD to the body more quickly and effectively than traditional formulations

Hundreds of CBD products competed to be among those named in "New Hope Network Editors' Top Picks for 2020,” published in January 2021

Lexaria Bioscience Corp (NASDAQ:LEXX) () announced that its corporate client Amari Corp's "Everyday Calm" CBD product was named a Top CBD Product Pick by New Hope Network, host of the industry-leading Natural Products Expo conference events.  

Lexaria provided Amari with its DehydraTECH technology, which delivers CBD to the body more quickly and effectively than traditional formulations, as shown in repeated studies. 

"Lexaria is delighted to have been able to work with Amari and their award-winning products," Lexaria CEO Chris Bunka said in a statement. "DehydraTECH is gaining more widespread consumer support, and we expect to see products utilizing DehydraTECH technology in more and more stores across America as the year unfolds." 

READ: Lexaria Bioscience to evaluate DehydraTECH in four drug markets

Hundreds of CBD products competed to be among those named in "New Hope Network Editors' Top Picks for 2020,” published in January 2021, the company said.

The new study programs will target NSAIDs, nicotine replacement therapies, tetrahydrocannabinol (THC), and erectile dysfunction 

Each study will evaluate the rate of absorption and speed (pharmacokinetics or PK assessments)

Lexaria Bioscience Corp (NASDAQ:LEXX) (), a global innovator in drug delivery platforms, said Tuesday it will begin important new applied research and development study programs.  

In a statement, the company said the new study programs will target four-drug markets, including NSAIDs, nicotine replacement therapies, tetrahydrocannabinol (THC), and erectile dysfunction. 

Lexaria added that each study will evaluate the rate of absorption and speed (pharmacokinetics or PK assessments) with which various new enhanced DehydraTECH experimental formulations – DehydraTECH 2.0 – deliver the drugs into the bloodstream and, in some cases the brain, after oral dosing. 

READ: Lexaria technology generates positive stability testing for ready-to-drink CBD beverages

“Our 2021 study program – already the largest in our company’s history – is growing,” said CEO Chris Bunka. “All of our studies are designed to generate must-have data, allowing us to have more meaningful business discussions with various industry leaders and as such, can shorten the time required for positive commercial developments.”

The maker of hard pill cannabinoid formulations said it can now fulfill the purchase order received from Australian hemp and medical cannabis group Cann Global Limited

The $406,200 Cann Global order includes six stock keeping units

Canntab Therapeutics Limited () (OTCQB:CTABF) (FRA:TBF1) said it has been granted an export license by Health Canada. 

The maker of hard pill cannabinoid formulations said it can now fulfill the purchase order received from Australian hemp and medical cannabis group Cann Global Limited () (FRA:54A).  The $406,200 order includes six stock-keeping units (SKUs) comprised of 2.5 milligrams (mg) tetrahydrocannabinol (THC), 5mg THC, 12.5mg cannabidiol (CBD), 25mg THC, and combined caplets (a hard-coated tablet in the shape of a capsule) with 5mg THC/25mg CBD and 2.5mg THC/12.5mg CBD. 

The order is expected to be distributed throughout Australia to medical distributors including doctors, pharmacies, and hospitals. 

WATCH: Canntab Therapeutics granted 3rd patent while also taking part in large medical cannabis study

Canntab said Cann Global is also expected to make the products it receives available to the Cannabinoid Medicine Observational Study (CMOS), which intends to collect data from 20,000 participants to assess the safety and efficacy of medicinal cannabis products for a range of refractory conditions including fibromyalgia, chronic pain syndromes, PTSD, epilepsy, and other mental health and neurological conditions. 

Lexaria Bioscience (CSE: LXX- Nasdaq: LEXXW) CEO Chris Bunka joined Steve Darling from Proactive to share news the company has released positive results from its extended stability testing for bottled CBD-containing beverages prepared using its technology.

Bunka telling Proactive Lexaria’s DehydraTECH CBD nanoemulsification formulation and processing techniques tested in beverages maintained their CBD content which was verified at 93.4% of target potency one year after production and also evidenced excellent microbial purity over this period.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

The company reported that by using its DehydraTECH technology CBD beverages demonstrated 93.4% potency one year after production

Lexaria's first patent was awarded in 2016 for CBD-infused beverages and consumable liquids

Lexaria Bioscience Corp (NASDAQ:LEXX) () shared Wednesday positive results from its extended stability testing, which showed unparalleled stability for bottled CBD drinks made using its technology. 

The Kelowna, British Columbia-based company’s patented DehydraTECH cannabidiol (CBD) nano-emulsification formulation and processing techniques, ensured the tested beverages maintained their CBD content, which was verified at 93.4% of target potency one year after production. The drinks also had “excellent microbial purity over this period,” said the company. 

In addition, the DehydraTECH ready-to-drink (RTD) beverages were tested for content uniformity and homogeneity of CBD distribution and demonstrated “less than 1% variability” in CBD potency in fractions sampled from the top, middle, and bottom of the drink without physical mixing. 

READ: Lexaria Bioscience reports progress in two antiviral drug studies in its 2021 applied R&D program

"I love reminding people that Lexaria's first patent was awarded in 2016 for CBD-infused beverages and consumable liquids," Lexaria CEO Chris Bunka said in a statement.

Two of the four planned studies using DehydraTECH with antivirals are progressing -- comprised of a SARS-CoV-2 infected human cell culture study (VIRAL-C21-3) and an animal research pharmacokinetic study (VIRAL-A20-2)

The drugs being studied in Lexaria’s 2021 antiviral program not only target SARS-CoV-2/COVID 19 applications, but also have existing utility across additional infectious diseases

Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) (OTCMKTS:LXR) announced Tuesday extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development (R&D) program.

“It’s been a very productive start into 2021 with a total of seven studies across our various research programs currently underway,” said Lexaria CEO Chris Bunka in a statement.

READ: Lexaria Bioscience updates on progress of its DehydraTECH CBD studies to treat high blood pressure

“Lexaria’s applied R&D programs are vital to generate the supportive data required to pursue either regulatory approvals or corporate relationships necessary for commercial launch. We expect great success this year and are eager to report study results as they become available,” Bunka added.

The company said that two of the four planned studies using DehydraTECH with antivirals are progressing -- comprised of one SARS-CoV-2 infected human cell culture study (VIRAL-C21-3) and one animal research pharmacokinetic study (VIRAL-A20-2).

Lexaria Bioscience (CSE: LXX-NASDAQ: LEXX- OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive to share details about the company’s three human clinical trials and two animal research trials. Bunka telling Proactive how these studies are going so far. The studies are using Lexaria’s DehydraTECH CBD for the treatment of hypertension and are being performed by third-party laboratories to ensure study objectivity.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

In human study HYPER-H21-1, the recruiting of 24 volunteers with otherwise untreated pre- or mild-hypertension has begun, and dosing using a single 300mg dose of CBD with or without DehydraTECH formulation enhancement is tentatively expected to be completed by May this year

Lexaria noted that the US annual hypertension drug market is worth US$28 billion, with direct healthcare costs for patients with pulmonary arterial hypertension estimated at between US$29,712 and $142,500 per year

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) has updated investors on the progress of assessing its DehydraTECH CBD technology in treating high blood pressure, noting that all five of its planned studies for this year are now underway.

Three human clinical trials and two animal research studies are in progress.

READ: Lexaria Bioscience expands DehydraTECH CBD hypertension program with two new human trials; updates for others

In the human study HYPER-H21-1, the recruiting of 24 volunteers with otherwise untreated pre- or mild-hypertension has begun, and dosing using a single 300mg dose of CBD with or without DehydraTECH formulation enhancement, is tentatively expected to be completed by May this year.

In human trial HYPER-H21-2, formal hospital and ethics board applications for an upcoming European study have been approved and test articles are expected to arrive at the research site as early as next week.  Following this, recruitment of 16 volunteers will start soon, said Lexaria.

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive with news the Australian Patent Office has granted Canntab an Australian Patent related to its proprietary cannabidiol formulations.

Goldstein talks about another validation of their technology with this patent and also the fact they have a purchase order from Australia. Goldstein also told Proactive the company will be taking part in Australia's Largest Observational Medical Cannabis Research Study ever.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In addition, the company has received an initial purchase order of $406,200 with its Australian partner, Cann Global Limited

Cann Global will participate in Australia's Cannabinoid Medicine Observational Study that will collect data from 20,000 patients nationwide over 5 years

Canntab Therapeutics Limited () (OTCQB:CTABF) (FRA:TBF1) announced Tuesday that the Australian Patent Office has granted the company a patent related to its proprietary cannabidiol formulations. 

In addition, the company reported it has now received an initial purchase order of $406,200 with its Australian partner, Cann Global Limited of Australia. 

The company said the patent expires on January 22, 2038 and has a priority date of January 23, 2017. 

READ: Canntab Therapeutics says it has completed its second delivery of two additional SKU's ordered by MediPharm Labs

"The allowance of Canntab's patent by the Australian Patent Office continues to further provide fundamental intellectual protection for Canntab's innovative tableting technology and even further validates the years of research and development the company has conducted,” said Canntab's Legal Counsel on intellectual property, Gavin Bogle of Magyar, Bogle & O'Hara LLP. “The company now has patent protection in the USA, Canada and Australia providing an international scope to the company's expanding portfolio of issued patents."

The company said the merger will create a leading company in the distribution of hemp and cannabinoid-based products, which will operate under the Global Cannabinoids corporate name following completion

The net proceeds of the private placement are expected to be used to fund the merger, the pro forma business plan of the resulting company and for general corporate purposes

EXMceuticals Inc. (CSE:EXM) (FRA:A2PAW2) has announced a proposed merger with Global Cannabinoids (GC), a leading B2B US distributor of bulk and wholesale hemp-derived cannabinoids and finished products., and has also launched a best-efforts, private placement for up to C$6.0 million.

The company said the merger will create a leading company in the distribution of hemp and cannabinoid-based products, which will operate under the Global Cannabinoids corporate name following completion, and which can conceivably expand beyond the US and import, export, research and refine cannabinoids and cannabis-based products through EXMceuticals' Portugal hub into the European Union.

READ: EXMceuticals joins The Portuguese Association of the Pharmaceutical Industry as it builds out cannabis extraction facility in Portugal

In a statement, Jonathan Summers, CEO of EXMceuticals said: "EXM could not be more excited to be combining operations with GC. As pioneers in the industry, the management team at GC have built a very impressive business footprint and distribution network while generating meaningful revenue. GC provides B2B customers with products and services that deliver an unmatched level of consistency and quality in the fastest possible time. We feel enormous growth opportunities exist in the US marketplace and beyond, with EXM’s operations in Portugal providing an immediate springboard to access the entire emerging European marketplace, for all legal cannabinoids."

“The team at EXM shares the same vision for the future as we do. GC’s commitment to quality, consistency and best in class pricing, combined with EXM’s global reach, will allow for rapid expansion to customers in emerging markets. We are incredibly excited for the opportunities ahead!” added Global Cannabinoids’ chief executive officer Kelly Ann Lewis-Bortman.

The company said it has now fulfilled 80% of the purchase amount contracted under the wholesale table purchase agreement entered into by the company and MediPharm Labs in June 2020

Canntab also said it is currently evaluating a number of partnering opportunities in Canada, the United States and Europe

Canntab Therapeutics Limited () (OTCQB:CTABF) (FRA:TBF1) said it has completed its second delivery of two additional SKU's ordered by Corp, including 12.5mg CBD caplets (hard tablets in the shape of capsules) and 25mg CBD caplets for approximately $550,000.00.

The company said it has now fulfilled 80% of the purchase amount contracted under the wholesale table purchase agreement entered into by the company and MediPharm Labs in June 2020. As Canntab announced on December 1, 2020, the total purchase order was approximately $1.3 million.

READ: Canntab Therapeutics granted Canadian patent for its hard pill cannabidiol formulations

The first delivery included 2.5mg THC and 5mg THC tablets. The final shipment which is currently in production and anticipated to be completed by month-end is for a combination caplet which contains 25mg CBD and 5mg THC.

In a statement, Larry Latowsky, chief executive officer of Canntab commented: "We are very pleased having shipped 2 more SKU's to Medipharm Labs. Not only will this shipment reflect our second consecutive quarter of revenue, but more importantly, it also reflects our ability to ramp up our production by now having successfully produced and delivered 4 unique SKU's including 2.5mg THC, 5mg THC, 12.5mg CBD and 25mg CBD hard oral dose tablets and caplets.

Study design for HYPER-A21-1 and HYPER-A21-2, both animal studies, has been completed, and dosing is expected to begin in late February or early March

Lexaria Bioscience Corp (NASDAQ:LEXX) () is expanding its applied research and development (R&D) program in 2021 with a particular focus on DehydraTECH-enabled CBD for hypertension, the company announced Thursday. 

The company’s hypertension program now consists of five planned studies, three of which were previously announced on February 1 (HYPER-A21-1, HYPER-A21-2, and HYPER-H21-1). Study design for HYPER-A21-1 and HYPER-A21-2, both animal studies, has been completed, and dosing is expected to begin in late February or early March.

HYPER-H21-1, as well as new additions HYPER-H21-2 and HYPER-H21-3, are randomized, double-blinded human clinical studies that will take place in Europe, the company said. Study design for HYPER-H21-1 is complete, and university hospital and ethics board approvals have been received. Dosing will begin after shipment of the clinical test articles to the clinical site is completed, pending regulatory clearances.

READ: Lexaria Bioscience plots applied R&D course to DehydraTECH CBD hypertension and antiviral studies

HYPER-H21-2 is designed to monitor ambulatory blood pressure during the 24-hour period after dosing, with subjects wearing portable devices that will record blood pressure at 30-minute and 60-minute intervals. Volunteers will receive a 150mg dose of DehydraTECH-CBD or a placebo three times daily. 

The company hopes that the results of this study will help it understand the effectiveness of DehydraTECH-processed CBD as a potential anti-hypertensive agent over a full day of monitoring, which complements the shorter-term monitoring in HYPER-H21-1. Study design for HYPER-H21-2 is complete and university hospital and ethics board approvals are pending.


MjInvest.com